CanSino Biologics Inc. (688185.SH): Application for Drug Registration of Adsorbed Acellular Combined Vaccine for Diphtheria, Tetanus, and Whooping Cough (Five Components) Accepted

date
16:01 16/08/2026
avatar
GMT Eight
Kangxino (688185.SH) announced that the drug registration application for its research and development of the acellular pertussis-diphtheria-tetanus combined vaccine (5-component) for use in individuals aged 6 years and older (referred to as "Td5cp for adolescents and adults") has recently received the "Acceptance Notice" issued by the National Medical Products Administration. Td5cp for adolescents and adults is suitable for individuals aged 6 and older and serves as a booster vaccine for pertussis, diphtheria, and tetanus for adolescents and adults. This vaccine has been included in routine vaccination programs in many developed countries, but there are currently no approved booster vaccines for pertussis, diphtheria, and tetanus for adolescents and adults in China. If successfully launched, this product will fill a gap in the domestic market.
CanSino Biologics Inc. (688185.SH) announced that its application for the production registration of the acellular combined vaccine for diphtheria, tetanus, and pertussis (5-component) for use in individuals aged 6 years and older (referred to as Td5cp for adolescents and adults) has recently received an acceptance notice from the National Medical Products Administration. The Td5cp for adolescents and adults is intended for people aged 6 and older as a booster vaccine for diphtheria, tetanus, and pertussis. This vaccine has been included in routine vaccination programs in many developed countries, but there are currently no approved booster vaccines for diphtheria, tetanus, and pertussis for adolescents and adults in China. If this product is successfully launched, it will fill a gap in the domestic market.